A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with advanced renal cell carcinoma

Authors: Kathryn E. Beckermann, Amita Patnaik, Ira Winer, Winston Tan, Babar Bashir, Christos E. Kyriakopoulos, Randy F. Sweis, Marc C. Chamberlain, Brian I. Rini - Investigational New Drugs 2024 cited by 30